Ken Fisher's PTCT Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 44,558 shares of PTC Therapeutics, Inc. (PTCT) worth $3.04 M, representing 0.00% of the portfolio. First purchased in 2016-Q1, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Ken Fisher has maintained a strategic position in PTCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2019, adding 135,289 shares. Largest reduction occurred in Q1 2024, reducing 95,778 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +44,558 | New Buy | 44,558 | $68.13 |
| Q1 2024 | -95,778 | Sold Out | 0 | $0.00 |
| Q4 2023 | -6,359 | Reduce 6.23% | 95,778 | $27.56 |
| Q3 2023 | -51,165 | Reduce 33.38% | 102,137 | $22.41 |
| Q2 2023 | -3,818 | Reduce 2.43% | 153,302 | $40.67 |
| Q1 2023 | -43,757 | Reduce 21.78% | 157,120 | $48.44 |
| Q4 2022 | -3,511 | Reduce 1.72% | 200,877 | $38.17 |
| Q3 2022 | -22,909 | Reduce 10.08% | 204,388 | $50.20 |
| Q2 2022 | +12,323 | Add 5.73% | 227,297 | $40.06 |
| Q1 2022 | +11,000 | Add 5.39% | 214,974 | $37.31 |
| Q4 2021 | +27,818 | Add 15.79% | 203,974 | $39.83 |
| Q3 2021 | +15,671 | Add 9.76% | 176,156 | $37.21 |
| Q2 2021 | +4,097 | Add 2.62% | 160,485 | $42.27 |
| Q1 2021 | +6,282 | Add 4.19% | 156,388 | $47.35 |
| Q4 2020 | -14,142 | Reduce 8.61% | 150,106 | $61.03 |
| Q3 2020 | -19,567 | Reduce 10.64% | 164,248 | $46.75 |
| Q2 2020 | -6,671 | Reduce 3.50% | 183,815 | $50.74 |
| Q1 2020 | -35,324 | Reduce 15.64% | 190,486 | $44.61 |
| Q4 2019 | -41,813 | Reduce 15.62% | 225,810 | $48.03 |
| Q3 2019 | -105 | Reduce 0.04% | 267,623 | $33.82 |
| Q2 2019 | +135,289 | Add 102.15% | 267,728 | $45.00 |
| Q4 2018 | -1,357 | Reduce 1.01% | 132,439 | $34.32 |
| Q3 2018 | -15,104 | Reduce 10.14% | 133,796 | $47.00 |
| Q2 2018 | -8,935 | Reduce 5.66% | 148,900 | $33.73 |
| Q1 2018 | -7,823 | Reduce 4.72% | 157,835 | $27.06 |
| Q4 2017 | -7,387 | Reduce 4.27% | 165,658 | $16.68 |
| Q3 2017 | +83,403 | Add 93.04% | 173,045 | $20.01 |
| Q1 2017 | +1,800 | Add 2.05% | 89,642 | $9.84 |
| Q4 2016 | -1,800 | Reduce 2.01% | 87,842 | $10.91 |
| Q2 2016 | +3,942 | Add 4.60% | 89,642 | $7.47 |
| Q1 2016 | +85,700 | New Buy | 85,700 | $8.91 |
Ken Fisher's PTC Therapeutics Investment FAQs
Ken Fisher first purchased PTC Therapeutics, Inc. (PTCT) in Q1 2016, acquiring 85,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held PTC Therapeutics, Inc. (PTCT) for 34 quarters since Q1 2016.
Ken Fisher's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q2 2019, adding 267,728 shares worth $12.05 M.
According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 44,558 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $3.04 M.
As of the Q1 2026 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in PTC Therapeutics, Inc. (PTCT) was 267,728 shares, as reported at the end of Q2 2019.